317 related articles for article (PubMed ID: 31744750)
1. Psychiatric drugs impact mitochondrial function in brain and other tissues.
Chan ST; McCarthy MJ; Vawter MP
Schizophr Res; 2020 Mar; 217():136-147. PubMed ID: 31744750
[TBL] [Abstract][Full Text] [Related]
2. Kv3.1-containing K(+) channels are reduced in untreated schizophrenia and normalized with antipsychotic drugs.
Yanagi M; Joho RH; Southcott SA; Shukla AA; Ghose S; Tamminga CA
Mol Psychiatry; 2014 May; 19(5):573-9. PubMed ID: 23628987
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
[TBL] [Abstract][Full Text] [Related]
4. Synaptic proteins in the postmortem anterior cingulate cortex in schizophrenia: relationship to treatment and treatment response.
Barksdale KA; Lahti AC; Roberts RC
Neuropsychopharmacology; 2014 Aug; 39(9):2095-103. PubMed ID: 24603856
[TBL] [Abstract][Full Text] [Related]
5. Pharmacotherapy of schizophrenia: Mechanisms of antipsychotic accumulation, therapeutic action and failure.
Chestnykh DA; Amato D; Kornhuber J; Müller CP
Behav Brain Res; 2021 Apr; 403():113144. PubMed ID: 33515642
[TBL] [Abstract][Full Text] [Related]
6. Do neurotensin receptor agonists represent a novel class of antipsychotic drugs?
Cáceda R; Kinkead B; Nemeroff CB
Semin Clin Neuropsychiatry; 2003 Apr; 8(2):94-108. PubMed ID: 12728409
[TBL] [Abstract][Full Text] [Related]
7. Serotonin receptors: their key role in drugs to treat schizophrenia.
Meltzer HY; Li Z; Kaneda Y; Ichikawa J
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic drug use complicates assessment of gene expression changes associated with schizophrenia.
Schulmann A; Marenco S; Vawter MP; Akula N; Limon A; Mandal A; Auluck PK; Patel Y; Lipska BK; McMahon FJ
Transl Psychiatry; 2023 Mar; 13(1):93. PubMed ID: 36932057
[TBL] [Abstract][Full Text] [Related]
9. The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment.
Weiner I
Psychopharmacology (Berl); 2003 Sep; 169(3-4):257-97. PubMed ID: 12601500
[TBL] [Abstract][Full Text] [Related]
10. FADD adaptor and PEA-15/ERK1/2 partners in major depression and schizophrenia postmortem brains: basal contents and effects of psychotropic treatments.
García-Fuster MJ; Díez-Alarcia R; Ferrer-Alcón M; La Harpe R; Meana JJ; García-Sevilla JA
Neuroscience; 2014 Sep; 277():541-51. PubMed ID: 25075716
[TBL] [Abstract][Full Text] [Related]
11. Co-administration of atypical antipsychotics and antidepressants disturbs contrast detection in schizophrenia.
Sheremata S; Chen Y
Schizophr Res; 2004 Sep; 70(1):81-9. PubMed ID: 15246467
[TBL] [Abstract][Full Text] [Related]
12. Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications.
McNamara RK; Jandacek R; Rider T; Tso P; Hahn CG; Richtand NM; Stanford KE
Schizophr Res; 2007 Mar; 91(1-3):37-50. PubMed ID: 17236749
[TBL] [Abstract][Full Text] [Related]
13. Evidence of Mitochondrial Dysfunction within the Complex Genetic Etiology of Schizophrenia.
Hjelm BE; Rollins B; Mamdani F; Lauterborn JC; Kirov G; Lynch G; Gall CM; Sequeira A; Vawter MP
Mol Neuropsychiatry; 2015 Dec; 1(4):201-19. PubMed ID: 26550561
[TBL] [Abstract][Full Text] [Related]
14. The role of serotonin receptors in the action of atypical antipsychotic drugs.
Meltzer HY; Massey BW
Curr Opin Pharmacol; 2011 Feb; 11(1):59-67. PubMed ID: 21420906
[TBL] [Abstract][Full Text] [Related]
15. Molecular Mechanisms of Antipsychotic Drug-Induced Diabetes.
Chen J; Huang XF; Shao R; Chen C; Deng C
Front Neurosci; 2017; 11():643. PubMed ID: 29209160
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial Complex I Deficiency in Schizophrenia and Bipolar Disorder and Medication Influence.
Rollins BL; Morgan L; Hjelm BE; Sequeira A; Schatzberg AF; Barchas JD; Lee FS; Myers RM; Watson SJ; Akil H; Potkin SG; Bunney WE; Vawter MP
Mol Neuropsychiatry; 2018 Feb; 3(3):157-169. PubMed ID: 29594135
[TBL] [Abstract][Full Text] [Related]
17. Update on typical and atypical antipsychotic drugs.
Meltzer HY
Annu Rev Med; 2013; 64():393-406. PubMed ID: 23020880
[TBL] [Abstract][Full Text] [Related]
18. Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort.
Fond G; Resseguier N; Schürhoff F; Godin O; Andrianarisoa M; Brunel L; Bulzacka E; Aouizerate B; Berna F; Capdevielle D; Chereau I; D'Amato T; Dubertret C; Dubreucq J; Faget C; Gabayet F; Lançon C; Llorca PM; Mallet J; Misdrahi D; Passerieux C; Rey R; Schandrin A; Urbach M; Vidailhet P; Boyer L; Leboyer M;
Eur Arch Psychiatry Clin Neurosci; 2018 Sep; 268(6):541-553. PubMed ID: 29127503
[TBL] [Abstract][Full Text] [Related]
19. Impact of second-generation antipsychotics on the use of antiparkinson agents in nursing homes and assisted-living facilities.
Touré JT; Brandt NJ; Limcangco MR; Briesacher BA
Am J Geriatr Pharmacother; 2006 Mar; 4(1):25-35. PubMed ID: 16730618
[TBL] [Abstract][Full Text] [Related]
20. Serotonergic mechanisms as targets for existing and novel antipsychotics.
Meltzer HY
Handb Exp Pharmacol; 2012; (212):87-124. PubMed ID: 23129329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
